Title: Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of
three non-invasive markers
Version: 2 Date: 25 Dec 2024
Reviewer's report:
The study presents a novel approach to diagnosing endoscopic remission (ER) in Crohn's disease
(CD) by combining three non-invasive markers: serum C-reactive protein (CRP), leucine-rich
alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal). The authors aimed to enhance the
diagnostic performance of ER by evaluating the efficacy of these markers in combination, rather
than in isolation, which has been the norm in previous studies.
I have some comments/concerns to be addressed:
1.The study's innovation is marginal, as it follows the established trend of multi-biomarker
assessments in IBD without introducing a transformative approach.Furthermore, it does not
compare the efficacy of the chosen biomarker panel with other panels proposed in similar past
studies, which limits the assessment of its relative performance and potential superiority.
2.The question at hand is why these 3 biomarkers were chosen when there are numerous other
non-invasive biomarkers available as candidates.
3.It is necessary to clarify the cut-off values and detection limits for LRG, CRP, and Fcal.
Concurrently, a test for normal distribution of the quantitative data must be conducted.
Title: Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of
three non-invasive markers
Version: 2 Date: 25 Dec 2024
Reviewer's report:
The study presents a novel approach to diagnosing endoscopic remission (ER) in Crohn's disease
(CD) by combining three non-invasive markers: serum C-reactive protein (CRP), leucine-rich
alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal). The authors aimed to enhance the
diagnostic performance of ER by evaluating the efficacy of these markers in combination, rather
than in isolation, which has been the norm in previous studies.
I have some comments/concerns to be addressed:
1.The study's innovation is marginal, as it follows the established trend of multi-biomarker
assessments in IBD without introducing a transformative approach.Furthermore, it does not
compare the efficacy of the chosen biomarker panel with other panels proposed in similar past
studies, which limits the assessment of its relative performance and potential superiority.
2.The question at hand is why these 3 biomarkers were chosen when there are numerous other
non-invasive biomarkers available as candidates.
3.It is necessary to clarify the cut-off values and detection limits for LRG, CRP, and Fcal.
Concurrently, a test for normal distribution of the quantitative data must be conducted.
Please review this paper.
user
Title: Efficient diagnosis for endoscopic remission in Crohn’s diseases by the combination of
three non-invasive markers
Version: 2 Date: 25 Dec 2024
Reviewer's report:
The study presents a novel approach to diagnosing endoscopic remission (ER) in Crohn's disease
(CD) by combining three non-invasive markers: serum C-reactive protein (CRP), leucine-rich
alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal). The authors aimed to enhance the
diagnostic performance of ER by evaluating the efficacy of these markers in combination, rather
than in isolation, which has been the norm in previous studies.
I have some comments/concerns to be addressed:
1.The study's innovation is marginal, as it follows the established trend of multi-biomarker
assessments in IBD without introducing a transformative approach.Furthermore, it does not
compare the efficacy of the chosen biomarker panel with other panels proposed in similar past
studies, which limits the assessment of its relative performance and potential superiority.
2.The question at hand is why these 3 biomarkers were chosen when there are numerous other
non-invasive biomarkers available as candidates.
3.It is necessary to clarify the cut-off values and detection limits for LRG, CRP, and Fcal.
Concurrently, a test for normal distribution of the quantitative data must be conducted.
assistant